Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy

In 'Safety, Tolerability, and Patient-Centered Decision Making in ASCVD Lipid Therapy,' our panel delves into the safety and tolerability landscape of lipid-lowering therapies, beginning with a reassessment of statin side effects. The panel references a recent Lancet meta-analysis indicating that only four of 66 reported statin side effects in package inserts are statistically significant in blinded outcomes trials, with the most clinically relevant concerns being a modest increase in glucose levels in patients at borderline risk for diabetes and occasional minor effects on liver function. The discussion then addresses the safety profile of PCSK9 inhibitors, with the panel noting that injectable monoclonal antibodies such as evolocumab and alirocumab are generally very well tolerated, with injection site reactions being rare and typically minor. A practical tip is offered for reducing injection discomfort by allowing the medication to reach room temperature before administration. The safety profile of inclisiran is similarly favorable, with only transient and clinically insignificant elevations in liver function tests noted, attributed to its liver-specific mechanism of activation that avoids muscle tissue, a point panelists find particularly useful when counseling patients concerned about musculoskeletal side effects. The emerging oral PCSK9 inhibitor enlicitide is also highlighted as showing tolerability comparable to placebo in trials of up to one year in duration, with the caveat that fasting is required to optimize absorption.

The conversation then shifts to patient-centered considerations around dosing frequency and route of administration, with the panel acknowledging that preferences vary widely between patients and even between prescribers, noting that endocrinologists tend to be more comfortable with injectables given their familiarity with insulin administration. The panelists discuss the practical trade-offs between daily oral therapy and less frequent injectable regimens, recognizing that while less frequent dosing can improve convenience, missed injection appointments in patients with unpredictable schedules can create treatment gaps. The episode concludes by emphasizing that shared decision-making, in which patients are actively involved in selecting the therapy that best fits their lifestyle, preferences, and access, is essential to optimizing adherence and achieving long-term LDL goals in ASCVD management.

Our next episode, 'Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy,' further explores ASCVD, highlighting the critical role of medication adherence and persistence in achieving sustained LDL lowering, and examining the practical strategies, shared decision-making, and patient-provider relationship factors that drive long-term treatment success.